Inhaled Loxapine as a Rapid Treatment for Agitation in Patients with Personality Disorder: A Prospective Study on the Effects of Time
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Agitation in patients diagnosed with personality disorders (PD) is one of the most frequent crises in emergency departments (ED). Although many medications have been tested, their effectiveness has been small or non-significant, and no specific drugs are supported by the available evidence. This study aimed to evaluate the efficacy of Inhaled loxapine (IL) as a therapeutic option for agitated patients with PD. Methods: A naturalistic, unicentric, prospective study was carried out. Thirty subjects diagnosed with PD and attending the ED with episodes of agitation were recruited most of whom were women diagnosed with Borderline Personality Disorder. Subjects were treated with a single dose of IL (9.1 mg). Efficacy was assessed with the Clinical Global Impression scale, the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) and the Agitation-Calmness Evaluation Scale (ACES). Patients were followed 60 minutes after administration to measure IL effect and its duration. Results: IL exhibited an overall efficacy in managing mild to severe agitation, with a quick onset of effect and persistence. ‘Effect of time’, where IL efficacy is maintained over time, is more marked in higher-severity agitation. No additional treatments were needed to improve agitation during the follow-up time. Conclusion: Results suggest that IL could be a safe and effective option to manage agitation in PD.
Abstract
Objective: Agitation in patients diagnosed with personality disorders (PD) is one of the most frequent crises in emergency departments (ED). Although many medications have been tested, their effectiveness has been small or non-significant, and no specific drugs are supported by the available evidence. This study aimed to evaluate the efficacy of Inhaled loxapine (IL) as a therapeutic option for agitated patients with PD. Methods: A naturalistic, unicentric, prospective study was carried out. Thirty subjects diagnosed with PD and attending the ED with episodes of agitation were recruited most of whom were women diagnosed with Borderline Personality Disorder. Subjects were treated with a single dose of IL (9.1 mg). Efficacy was assessed with the Clinical Global Impression scale, the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) and the Agitation-Calmness Evaluation Scale (ACES). Patients were followed 60 minutes after administration to measure IL effect and its duration. Results: IL exhibited an overall efficacy in managing mild to severe agitation, with a quick onset of effect and persistence. ‘Effect of time’, where IL efficacy is maintained over time, is more marked in higher-severity agitation. No additional treatments were needed to improve agitation during the follow-up time. Conclusion: Results suggest that IL could be a safe and effective option to manage agitation in PD.
참고문헌 (32)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
- Zeller SL, "Systematic reviews of assessment measures and pharmacologic treatments for agitation", Clin Ther, 32, pp.403~425 (2010)
- San L, "State of acute agitation at psychiatric emergencies in Europe : the STAGE study", Clin Pract Epidemiol Ment Health, 12, pp.75~86 (2016)
- Sachs GS, "A review of agitation in mental illness : burden of illness and underlying pathology", J Clin Psychiatry, 67(Suppl 10), pp.5~12 (2006)
- Allen MH, "Use of restraints and pharmacotherapy in academic psychiatric emergency services", Gen Hosp Psychiatry, 26, pp.42~49 (2004)
- Garriga M, "Assessment and management of agitation in psychiatry : expert consensus", World J Biol Psychiatry, 17, pp.86~128 (2016)
- Fossati A, "Predicting borderline and antisocial personality disorder features in nonclinical subjects using measures of impulsivity and aggressiveness", Psychiatry Res, 125, pp.161~170 (2004)
- Borschmann R, "Crisis interventions for people with borderline personality disorder", Cochrane Database Syst Rev, (6), pp.CD009353~ (2012)
- Martínez-Raga J, "1st International Experts' Meeting on Agitation : conclusions regarding the current and ideal management paradigm of agitation", Front Psychiatry, 9, pp.54~ (2018)
- Wilson MP, "The psychopharmacology of agitation : consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup", West J Emerg Med, 13, pp.26~34 (2012)
- Mancuso CE, "Paradoxical reactions to benzodiazepines : literature review and treatment options", Pharmacotherapy, 24, pp.1177~1185 (2004)
- Saïas T, "Paradoxical aggressive reactions to benzodiazepine use: a review", Encephale, 34, pp.330~336 (2008)
- Pascual JC, "Injectable atypical antipsychotics for agitation in borderline personality disorder", Pharmacopsychiatry, 39, pp.117~118 (2006)
- Ingenhoven T, "Effectiveness of pharmacotherapy for severe personality disorders : meta-analyses of randomized controlled trials", J Clin Psychiatry, 71, pp.14~25 (2010)
- Singh AN, "A neurochemical basis for the antipsychotic activity of loxapine : interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes", J Psychiatry Neurosci, 21, pp.29~35 (1996)
- Horn M, "Drug management of agitation in emergency departments: theoretical recommendations and studies of practices", Presse Med, 44, pp.20~26 (2015)
- Spyker DA, "Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens", J Clin Pharmacol, 55, pp.985~994 (2015)
- Bourdinaud V, "Survey of management methods for patients in a state of agitation at admission and emergency departments in France", Encephale, 29, pp.89~98 (2003)
- Shader RI, "ClinicalTrials.gov, inhaled loxapine, and safety issues", J Clin Psychopharmacol, 37, pp.119~121 (2017)
- "Spravato® (esketamine) summary of product characteristics" (2019)[URL]
- Allen MH, "Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia : a randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 72, pp.1313~1321 (2011)
- Kwentus J, "Rapid acute treatment of agitation in patients with bipolar I disorder : a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine", Bipolar Disord, 14, pp.31~40 (2012)
- Roncero C, "Inhaled loxapine for agitation in intoxicated patients : a case series", Clin Neuropharmacol, 40, pp.281~285 (2017)
- Patrizi B, "Inhaled loxapine for agitation in patients with personality disorder : an initial approach", Eur Neuropsychopharmacol, 29, pp.122~126 (2019)
- Kahl KG, "Inhaled loxapine for acute treatment of agitation in patients with borderline personality disorder : a case series", J Clin Psychopharmacol, 35, pp.741~743 (2015)
- Guy W, "ECDEU assessment manual for psychopharmacology:revised", pp.217~222 (1976), United States. Alcohol, Drug Abuse, and Mental Health Administration
- Busner J, "The clinical global impressions scale:applying a research tool in clinical practice", Psychiatry(Edgmont), 4, pp.28~37 (2007)
- Lindenmayer JP, "Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale", Psychopathology, 41, pp.264~270 (2008)
- Montoya A, "Validation of the Excited Component of the Positive and Negative Syndrome Scale(PANSS-EC)in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room", Health Qual Life Outcomes, 9, pp.18~ (2011)
- Shaikh U, "Patients with borderline personality disorder in emergency departments", Front Psychiatry, 8, pp.136~ (2017)
- Esler M, "The neuronal noradrenaline transporter, anxiety and cardiovascular disease", J Psychopharmacol, 20(4 Suppl), pp.60~66 (2006)
- Hůla J, "Psychological factors and heart diseases", Cas Lek Cesk, 137, pp.643~646 (1998)